SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron
Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage
biotechnology company focused on improving the lives of patients by
developing best-in-class treatments to address some of the most
important unmet patient needs, today announced the appointment of
Steve Davis to Heron's Board of
Directors.
"I am pleased to welcome Steve to the Heron Board," said Barry
Quart, Pharm.D., President and Chief Executive Officer of Heron.
"Steve's executive leadership in commercial organizations and
public-company board of directors experience in the
biopharmaceutical industry will be invaluable to Heron. We look
forward to his contributions to our Board."
Mr. Davis has served as Chief Executive Officer and as a
director of ACADIA Pharmaceuticals Inc. since 2015 and, previously,
as Executive Vice President, Chief Financial Officer and Chief
Business Officer from 2014 to 2015. Mr. Davis has more than 25
years of experience in the biopharmaceutical industry. Since 2015,
Mr. Davis has served as a director of Bellicum Pharmaceuticals,
Inc. From 2012 to 2015, he served as a director of Heron, and, from
2013 to 2014, he served as Executive Vice President, Chief
Operating Officer of Heron. Mr. Davis also served as a director of
Synageva Biopharma Corp. from 2011 through its acquisition by
Alexion Pharmaceuticals, Inc. in 2015. From 2013 to 2014, he served
as a director of Furiex Pharmaceuticals, Inc. through its
acquisition by Forest Laboratories, Inc. in 2014. Mr. Davis served
as Executive Vice President and Chief Operating Officer of Ardea
Biosciences, Inc. from 2010 through its acquisition by AstraZeneca
PLC in 2012. Previously, he held various positions at Neurogen
Corporation, most recently serving as President and Chief Executive
Officer. Prior to Neurogen, Mr. Davis practiced as a corporate and
securities attorney at a Wall Street law firm and practiced as a
certified public accountant at a major accounting firm. Mr. Davis
received a J.D. degree from Vanderbilt
University and a B.S. degree in accounting from Southern Nazarene University.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage
biotechnology company focused on improving the lives of patients by
developing best-in-class treatments to address some of the most
important unmet patient needs. Heron is developing novel,
patient-focused solutions that apply its innovative science and
technologies to already-approved pharmacological agents for
patients suffering from pain or cancer. For more information,
visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as
defined by the Private Securities Litigation Reform Act of 1995.
Heron cautions readers that forward-looking statements are based on
management's expectations and assumptions as of the date of this
news release and are subject to certain risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, but are not limited to, risks and
uncertainties identified in the Company's filings with the
Securities and Exchange Commission. Forward looking statements
reflect our analysis only on their stated date, and Heron takes no
obligation to update or revise these statements except as may be
required by law.
Investor Relations and Media Contact:
David Szekeres
Senior VP, General Counsel, Business Development and Corporate
Secretary
Heron Therapeutics, Inc.
dszekeres@herontx.com
858-251-4447
View original
content:http://www.prnewswire.com/news-releases/heron-therapeutics-appoints-stephen-davis-to-board-of-directors-300928987.html
SOURCE Heron Therapeutics, Inc.